Related Experiment Video
Updated: Mar 30, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
[YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?]
P S Holm1, M Retz2, J E Gschwend2
1Urologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, Ismaninger Straße 22, 81675, München, Deutschland. per.s.holm@lrz.tum.de.
Abstract:
Therapeutic intervention using oncolytic viruses is called virotherapy. This type of virus is defined by the ability to replicate in tumor cells only and to destroy these cells upon replication. In addition, this virus type is able to induce a tumor-directed immune response. Early clinical trials have confirmed the safety profile of oncolytic viruses. Currently, different groups are working on the development of oncolytic viruses with a focus on treatment of nonmuscle invasive bladder cancer (NMIBC). A preliminary active recruiting clinical phase II/III trial ongoing in patients with a NMIBC was recently implemented in the United States. Our research group developed an oncolytic adenovirus that will soon enter a clinical phase I trial in patients diagnosed with glioma. This virus is being further modified for the treatment of NMIBC. In this review article, recent developments in the design and use of virotherapy in bladder cancer are summarized.
Insights
Virotherapy uses oncolytic viruses to selectively destroy cancer cells and stimulate an immune response. Research is advancing oncolytic virus applications for nonmuscle invasive bladder cancer (NMIBC).
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Virotherapy, a therapeutic approach using oncolytic viruses, selectively replicates within and destroys tumor cells.
- Oncolytic viruses possess the unique ability to elicit a tumor-directed immune response.
- Early clinical trials have established a favorable safety profile for oncolytic viruses.
Purpose of the Study:
- To review recent advancements in the design and application of virotherapy for bladder cancer treatment.
- To highlight the development of oncolytic viruses targeting nonmuscle invasive bladder cancer (NMIBC).
Main Methods:
- Summary of current research and clinical trial data on virotherapy in bladder cancer.
- Discussion of oncolytic virus development, including oncolytic adenoviruses.
- Focus on modifications for NMIBC treatment.
Main Results:
- Oncolytic viruses demonstrate safety and efficacy in preclinical and early clinical studies.
- Ongoing clinical trials are investigating oncolytic viruses for NMIBC.
- Development of modified oncolytic adenoviruses for glioma and NMIBC is underway.
Conclusions:
- Virotherapy shows significant promise as a treatment modality for bladder cancer.
- Continued research and clinical trials are crucial for optimizing oncolytic virus therapies for NMIBC.
- Oncolytic viruses offer a novel strategy for cancer treatment, potentially enhancing immune responses against tumors.
More Related Videos
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
08:43An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy